Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV

By sjmartinez • April 9, 2025

Daar ES, Orkin C, Sax PE, Hagins D, Pozniak A, Workowski K, Brinson C, Tiraboschi JM, Liu H, Deaton C, Cohen C, Madera S, Hindman JT, Ramgopal M. Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV. AIDS Res Ther. 2025 Apr 7;22(1):45. doi: 10.1186/s12981-025-00732-w. PMID: 40197415; PMCID: PMC11978100.

Tags: antiretroviral therapy, Bictegravir, body mass index, dolutegravir, glucose, Harbor UCLA, HIV-1, Infectious Diseases, Publications, Tenofovir alafenamide

Pulmonary Rehabilitation Referral Practice Patterns across Lung Transplant Centers in the US: A Multi-Center Survey-Based Study

Deleija JD, Shah SZ, Felzer J, Garvey C, DeCato TW, Pennington K, Sehgal S, Kennedy C, Kumar A. Pulmonary Rehabilitation Referral Practice Patterns across Lung[...]

Vigorous But Not Moderate Physical Activity Is Associated With Reduced Cardiovascular Disease Risk In Young Hispanic Men

Gattoni C, Bebe K, Bross R, Wang C, Swerdloff RS, Oudiz RJ, Kraus WE, Rossiter HB. Vigorous But Not Moderate Physical Activity Is Associated With[...]

Nrf2- and p53-inducible REDD2/DDiT4L/Rtp801L confers pancreatic β-cell dysfunction, leading to glucose intolerance in high-fat diet-fed mice

Yamada Y, Urakawa N, Tamiya H, Sakamoto S, Takahashi H, Harada N, Kitakaze T, Izawa T, Matsumua S, Yoshihara E, Inui H, Mashimo T, Yamaji[...]